Skip to content
Sign in

Business opportunities

Who each startup should sell to, sell through, build with, enter a market with or raise from, read from the whole network. Every opportunity comes with its reasoning, the evidence and a first step.

SWC 2026 Finalist

BILIX

KAIST spin-off developing PEGylated bilirubin BX-001N to prevent acute kidney injury after cardiac surgery, now in phase 2a in Korea.

Open the dossier
Opportunities
4
High confidence
070% and above
Counterparts
4startups and investors
  • Customers 1
  • Investors 2
  • Peers 1

Customers1

Who could buy, or sell through

Buy Latin American real-world data to design phase 2b/3 and select sites

Phase 2b/3 design needs AKI incidence after cardiac surgery, baseline risk and site volumes. Cromodata's hospital network in five Latin American countries can supply de-identified cohorts and identify high-volume sites. Bilix gets cheaper trial design and new geographies; Cromodata gets a named pharma-type buyer.

30%confidence

Evidence from the records

  • “Marketplace in operation: claimed network of 47 to 84+ healthcare facilities in 5 countries (Argentina, Uruguay, Mexico, Dominican Rep., Brazil); no data buyer publicly named.”
  • “BX-001N: phase 1 completed (51 volunteers, Australia), phase 2a under way in Korea (NCT07164833) with KDDF support.”
If it works
A feasibility dataset and shortlisted LatAm sites for later trials.
First step
Send Cromodata a cohort definition (cardiac surgery, creatinine follow-up) and request a feasibility count.

Investors2

A fund whose thesis fits

Approach Sands Capital for the Series C, via PolyJoule

Sands Capital invests at Series A and later in biotech and medtech globally, matching Bilix's late-private stage. It is reported as an investor in PolyJoule in the network.

20%confidence

Evidence from the records

  • “Sands Capital Ventures and others (according to aggregators)”
  • “High risk: phase 2 clinical risk and large funding needs despite US$13M raised.”
If it works
A global growth-stage biotech investor for the post-phase-2a round.
First step
Ask PolyJoule's CEO for an intro to Sands Capital's life-science team.

Pitch EFung Capital, Pleryon's biotech investor

EFung invests at Series A and later in biotech in China and globally and backed Pleryon Therapeutics in the network; an Asian investor fits a Korean asset seeking regional licensing.

20%confidence

Evidence from the records

  • “EFung Capital (cited by CB Insights and Caplight); other historical investors: Zero2IPO, Kaitai Capital, Lapam Capital, HKUST R&D Corporation”
  • “Successful phase 1”
If it works
Capital plus access to Chinese licensing partners.
First step
Ask Pleryon's team for an intro to EFung Capital.

Peers1

Founders solving the same problem elsewhere

Exchange on polymer-drug CMC and Asian licensing

Both companies develop polymer-based therapeutics at Series A in Asia. Sharing CMC suppliers, regulatory strategy and licensing contacts reduces cost and time for both.

20%confidence

Evidence from the records

  • “Proprietary platforms for designing and controlling the structure of large synthetic and modified natural polymers, for drug delivery and injectable biomaterials.”
  • “PEGylated bilirubin nanomedicine platform (antioxidant and immunomodulatory activity)”
If it works
Shared vendor lists and licensing introductions.
First step
Arrange a CEO call during the Grand Finale.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai

Most promising across the network

587 opportunities analysed
  1. ORA TechnologieswithPwn&PatchCustomers
    Buy continuous threat-exposure management for the payments stack

    A payment super-app is a prime target for fraud and intrusion, and regulators expect continuous security testing. Pwn&Patch, a North African offensive-security firm with a CTEM platform, can cover attack-surface monitoring and continuous pentesting in French/Arabic, at regional cost. ORA reduces regulatory and breach risk; Pwn&Patch wins a flagship fintech reference in Morocco.

    50%
  2. Pwn&PatchwithORA TechnologiesCustomers
    Win ORA's super-app as a flagship fintech client

    ORA's payment super-app is exposed to regulatory and fraud risk and has no documented security partner. A continuous testing contract gives Pwn&Patch a Moroccan reference in fintech.

    45%
  3. UnitSensewithOrbisCustomers
    Cut Orbis's triple-model interview cost

    Orbis scores every interview with three independent AI models voting by majority, which multiplies inference cost per candidate in a price-sensitive SME market (Jordan, GCC, Egypt). UnitSense's per-request attribution and cheapest-good-enough routing directly targets that cost structure and gives Orbis a per-customer margin view.

    45%
  4. License TIBOK as a white-label engine for Baika

    Instead of building its own stack, Teramed could run Baika+Saúde on TIBOK's white-label OS (own brand, WhatsApp and phone numbers, Portuguese workspace) with pay-per-consultation pricing. It accelerates launch and reduces capex; TIBOK gains an Angolan distributor.

    40%
  5. EqorewithPolyJouleCustomers
    Deploy non-flammable polymer batteries at sensitive sites

    Some industrial sites have strict fire codes; PolyJoule's non-flammable, UL9540A-certified polymer batteries suit them. Eqore gains a differentiated product, PolyJoule a deployment channel.

    40%
  6. FarmbookerwithRegenrateCustomers
    Monitor 1,000+ ha of contracted cover crops

    Regenrate contracts farmers to grow camelina between main crops with a guaranteed price; it must verify sowing, crop development and expected volumes across many farms. Farmbooker's satellite monitoring provides that at scale, as a B2B per-hectare contract.

    40%
  7. PolyJoulewithEqoreCustomers
    Supply non-flammable cells for Eqore's on-site industrial batteries

    Eqore installs behind-the-meter batteries at industrial sites, including heat treatment and die casting where fire risk matters. Both companies are in Massachusetts. PolyJoule's safe chemistry could become Eqore's differentiated option.

    40%
  8. Pulster.aiwithVenditekCustomers
    Optimise Venditek’s vending-machine placement

    Venditek runs about 60 machines in Guatemala and is expanding to Mexico, laundromats and car washes; each misplaced machine is lost capex. Pulster's site-sales prediction, already proven for convenience chains like OXXO, applies directly to micro-locations.

    40%
  9. UnitSensewithKetzaiCustomers
    Unit-cost control for 40,000 teachers on Gemini

    Ketzai serves a large, mostly non-paying teacher base on a paid Gemini plan while its monetisation is unclear; cost per lesson plan is the core margin variable. UnitSense can attribute spend per school/ministry contract and route simpler generations to cheaper models.

    40%
  10. HardshellwithCromodataCustomers
    Certify Cromodata's clinical datasets against leakage and poisoning

    Cromodata sells de-identified clinical data for AI training; buyers will ask for assurance against re-identification and contamination. Hardshell's scans give Cromodata a trust label and Hardshell a commercial, non-defence reference.

    40%
  11. StemSightwithDefined BioscienceCustomers
    Qualify defined, serum-free media for StemSight's manufacturing process

    Moving iPSC-derived cells to the clinic requires defined, low-variability media; Defined Bioscience sells exactly this for pluripotent stem cells. A supply and co-development agreement lowers StemSight's cost of goods and gives Defined Bioscience a clinical-pathway customer.

    40%
  12. Allergen AlertwithNuhproCustomers
    Verified free-from claims for 'Food as Medicine' brands

    Nuhpro sells functional foods targeting intolerances and digestive disorders, where trust in 'free-from' claims is the product. A portable allergen test lets Nuhpro verify batches and co-market verification to consumers, giving Allergen Alert an early B2B design partner.

    35%
  13. CromodatawithLegit.HealthCustomers
    Supply Latin American skin images for model training and validation

    Legit.Health's CE-marked dermatology AI needs diverse skin types for performance and bias validation. Cromodata's imaging-rich network can supply de-identified, labelled datasets, giving Cromodata a named buyer and Legit.Health data for LatAm expansion.

    35%
  14. Defined BiosciencewithStemSightCustomers
    Design-in before StemSight's clinical process is locked

    StemSight is developing iPSC-derived corneal cells with clinical trials targeted around 2027; media choice now will be locked into its regulated process. A collaboration to qualify Defined Bioscience media for its differentiation protocol could create a long-term clinical customer and generate comparative data.

    35%
  15. Monte Caldera Technologies Inc.withSuper Foam Corp.Customers
    Model Super Foam’s PFAS-free formulations in Caldera Engine

    Super Foam casts a patented PFAS-free foam with adjustable formulation and density for each customer part; predicting properties before casting would cut iterations. It is an ideal first case study for Caldera's suspension physics.

    35%
  16. UnitSensewithWiseUnitCustomers
    Voice-agent cost governance for an AI receptionist

    WiseUnit sells a fixed monthly AI receptionist while its voice/LLM costs vary per call; UnitSense explicitly covers voice providers and voice-agent platforms, so it can protect WiseUnit's gross margin per subscriber.

    35%
  17. Neurath AIwithOmniLoc AICustomers
    Confidence bounds for GPS-free positioning

    OmniLoc's AI computes absolute position from camera-to-satellite matching; drone OEMs and defence users need to know when that estimate is unreliable. Neurath's uncertainty quantification can deliver calibrated confidence and identify terrain where more imagery is needed.

    35%
  18. TatraSpacewithTRL11Customers
    Sell flight-software verification to TRL11 ahead of first flight

    TRL11 builds onboard edge-compute video systems with contracts from NASA, Vast and Portal but no documented flight heritage yet, so rigorous ground testing is critical. WisentWire offers remote, CI-integrated testing of firmware against hardware.

    35%
  19. TatraSpacewithAstrolightCustomers
    Firmware testing and payload integration for laser terminals

    Astrolight is moving from test terminals to operational optical-communication networks with ESA and primes; each iteration of terminal firmware needs regression testing. TatraSpace is a nearby Central European supplier with payload-integration experience.

    35%
  20. Piezo Sonic CorporationwithAstrolightCustomers
    Qualify piezo actuators for laser-terminal fine pointing

    Optical terminals need precise, vacuum-compatible fine-pointing and focus mechanisms; ultrasonic motors are a natural fit because they hold position without power and work in vacuum. Astrolight is scaling a terminal product line with ESA and defence customers, so a qualified Japanese actuator source is valuable to it.

    35%

Similar profiles

Compatibility score with BILIX

Scored on needs and offers, market bridge, customer potential, sector synergy and stage. Open a profile to see each dimension.